Corbus Pharmaceuticals CEO and leadership

Yuval Cohen is a Co-Founder at Akari Therapeutics PLC; Chief Executive Officer at CORBUS PHARMACEUTICALS HOLDINGS, INC.; and Board Member at CORBUS PHARMACEUTICALS HOLDINGS, INC. and is based in Cambridge, Massachusetts. He has worked as SVP at CELSUS, President at Morria Biopharmaceuticals Plc, and President/CEO/Founder at Akari Therapeutics PLC. Yuval attended Univ Paris V Rene Descartes, Paris Las Vegas, and Cape Peninsula University of Technology between 2002 and 2002.

Sean Moran, CPA, joined Corbus in January 2014. He has more than twenty years of senior financial experience with emerging biotechnology, drug delivery and medical device companies. Mr. Moran has successfully managed operations from start up through development to commercialization and profitability. He has completed three IPOs and has raised over $200 million of capital. Before joining Corbus, Mr. Moran served as Chief Financial Officer for InVivo Therapeutics, Celsion Corporation, Echo Therapeutics, and Anika Therapeutics. Mr. Moran is a CPA and MBA by training having earned his M.B.A. and a B.S. in Accounting from Babson College.

Craig Millian joined Corbus as Chief Commercial Officer in February 2019. Mr. Millian brings 25 years of experience leading commercial organizations for a range of pharmaceutical companies as well as a successful track record building pharmaceutical brands during all stages of development and commercialization. Prior to joining Corbus, Mr. Millian held various leadership positions at EMD Serono, including Senior Vice President, Head of U.S. Fertility and Endocrinology, and Senior Vice President, Head of U.S. Neurology and Immunology. In these roles, he was responsible for leading the strategic direction and driving operating results for these franchises in the U.S. He oversaw key areas of the business, including sales, marketing and patient support services. Previously, Mr. Millian served as Vice President, Commercial at Vertex, where he helped design and build the commercial infrastructure, organizational capabilities and go-to-market plans in advance of launching the Vertex product pipeline. Prior to Vertex, he held commercial leadership roles at Pfizer Inc. and Sanofi. Mr. Millian holds an MBA from New York University and a degree in Finance from the University of Pennsylvania.

Yuval Cohen is a Co-Founder at Akari Therapeutics PLC; Chief Executive Officer at CORBUS PHARMACEUTICALS HOLDINGS, INC.; and Board Member at CORBUS PHARMACEUTICALS HOLDINGS, INC. and is based in Cambridge, Massachusetts. He has worked as SVP at CELSUS, President at Morria Biopharmaceuticals Plc, and President/CEO/Founder at Akari Therapeutics PLC. Yuval attended Univ Paris V Rene Descartes, Paris Las Vegas, and Cape Peninsula University of Technology between 2002 and 2002.

Sean Moran, CPA, joined Corbus in January 2014. He has more than twenty years of senior financial experience with emerging biotechnology, drug delivery and medical device companies. Mr. Moran has successfully managed operations from start up through development to commercialization and profitability. He has completed three IPOs and has raised over $200 million of capital. Before joining Corbus, Mr. Moran served as Chief Financial Officer for InVivo Therapeutics, Celsion Corporation, Echo Therapeutics, and Anika Therapeutics. Mr. Moran is a CPA and MBA by training having earned his M.B.A. and a B.S. in Accounting from Babson College.

Yuval Cohen is a Co-Founder at Akari Therapeutics PLC; Chief Executive Officer at CORBUS PHARMACEUTICALS HOLDINGS, INC.; and Board Member at CORBUS PHARMACEUTICALS HOLDINGS, INC. and is based in Cambridge, Massachusetts. He has worked as SVP at CELSUS, President at Morria Biopharmaceuticals Plc, and President/CEO/Founder at Akari Therapeutics PLC. Yuval attended Univ Paris V Rene Descartes, Paris Las Vegas, and Cape Peninsula University of Technology between 2002 and 2002.

Barbara White, M.D., joined Corbus as Chief Medical Officer in June 2014. Dr. White's industry experience includes Phase 1-4 clinical development experience in inflammatory and autoimmune diseases, including rheumatology, respiratory, and dermatology diseases. She also has industry experience in preclinical drug development, translational medicine and medical affairs. Prior to joining Corbus, Dr. White was Senior Vice President and Head of R&D at Stiefel, a GSK company. She has held roles at UCB, MedImmune and Amgen. Prior to her pharmaceutical career, Dr. White was Professor of Medicine and Vice Chair for Research in the Department of Medicine at the University of Maryland School of Medicine. Her research has focused on T cells and immune-mediated mechanisms of lung fibrosis in scleroderma. She also previously served as co-director of the Johns Hopkins University and University of Maryland Scleroderma Center. Dr. White received her medical degree from the University of Pennsylvania School of Medicine and is board certified in internal medicine, rheumatology and allergy/clinical immunology. She completed her postdoctoral studies in basic cellular immunology at the National Institutes of Health.